Exact Sciences Q4 screening revenue up 61 percent
post-template-default,single,single-post,postid-169480,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive

Exact Sciences Q4 screening revenue up 61 percent

Exact Sciences Q4 screening revenue up 61 percent

Exact Sciences logoExact Sciences brought in about $230 million in screening revenue during the fourth quarter of last year, according to the company’s latest preliminary financial report.

Screening revenue for that period was 61 percent higher than in the last three months of 2018, the report shows.

The Madison company’s acquisition of Genomic Health closed during the fourth quarter, so the financial report captures revenue from precision oncology services from Nov. 8 through the end of the year. Precision oncology revenue for that period was nearly $66 million, and projected precision oncology revenue for the full fourth quarter was nearly $119 million — 13 percent higher than Genomic Health’s comparable standalone performance.

Going into 2020, Chairman and CEO Kevin Conroy says the company is poised to change the way cancer is diagnosed and treated.